Lisanti Capital Growth LLC Sells 11,715 Shares of Repligen Co. (NASDAQ:RGEN)

Lisanti Capital Growth LLC cut its holdings in Repligen Co. (NASDAQ:RGEN) by 82.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,425 shares of the biotechnology company’s stock after selling 11,715 shares during the period. Lisanti Capital Growth LLC’s holdings in Repligen were worth $436,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. abrdn plc increased its position in Repligen by 1.4% in the 4th quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock worth $934,000 after buying an additional 71 shares during the period. Signaturefd LLC increased its position in Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 86 shares during the period. First Horizon Advisors Inc. raised its stake in Repligen by 14.8% during the 3rd quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 87 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in Repligen by 3.2% in the 3rd quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company’s stock valued at $509,000 after purchasing an additional 100 shares during the period. Finally, State of Michigan Retirement System grew its position in Repligen by 0.8% in the 4th quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock worth $2,239,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity at Repligen

In other news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, COO James Bylund sold 4,373 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the sale, the chief operating officer now directly owns 14,135 shares in the company, valued at approximately $2,799,860.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the sale, the director now owns 87,367 shares in the company, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders sold 25,597 shares of company stock valued at $5,039,532 in the last ninety days. Insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of RGEN traded down $0.32 during mid-day trading on Tuesday, reaching $167.72. The company had a trading volume of 529,350 shares, compared to its average volume of 540,044. The company’s 50-day moving average is $180.34 and its 200-day moving average is $174.47. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. The company has a market capitalization of $9.37 billion, a P/E ratio of 672.19, a P/E/G ratio of 5.58 and a beta of 1.03. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The company had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. During the same quarter in the prior year, the company earned $0.64 earnings per share. The business’s revenue was down 17.1% compared to the same quarter last year. On average, equities analysts anticipate that Repligen Co. will post 1.46 EPS for the current year.

Wall Street Analyst Weigh In

RGEN has been the subject of several research reports. KeyCorp increased their target price on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Stifel Nicolaus raised their price objective on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Finally, JPMorgan Chase & Co. decreased their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $197.75.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.